Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.
Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.
复制标题
DOI：
10.2147/opth.s6369
复制
发表时间：
2010-10-21
期刊：
影响因子：
--
通讯作者：
Pozarowska D
中科院分区：
文献类型：
--
作者：
Pozarowska D
青光眼是最常见的视神经病变之一。升高的眼内压（IOP）是这种疾病发展和进展的一个有据可查的风险因素。到目前为止，眼压降低是唯一有据可查的成功的青光眼治疗方法。在众多的抗青光眼药物中，前列腺素类似物被证明是最有效的抗青光眼药物，全身副作用很少。一种新的前列腺素类FP受体类似物他氟前列素已被引入青光眼和高眼压症的药物治疗中。许多研究表明，它是一种有效的降眼压药物，并且安全且耐受性良好。不含防腐剂的他氟前列素制剂与防腐剂一样有效，但对眼睛的毒性作用更少、更轻。
Glaucoma is one of the most common neuropathies of the optic nerve. An elevated intraocular pressure (IOP) is a well documented risk factor for the development and progression of this disease. Until now, IOP reduction is the only well documented successful method of glaucoma treatment. Among the many hypotensive drugs, prostaglandin analogs are proved to be the most potent antiglaucoma agents, with very few systemic side effects. A new prostanoid FP receptor analog, tafluprost, has been introduced into the medical treatment of glaucoma and ocular hypertension. Many studies have shown that it is an efficient IOP-lowering drug, and that it is safe and well tolerated. A preservative-free tafluprost formulation is as potent as a preserved one, but it has fewer and milder toxic effects on the eye.